ライフサイエンスコーパス: DMF

1 DMF also modulated B-cell MHC II expression and reduced

2 DMF and, more so, its active metabolite, monomethyl fuma

3 DMF in vitro treatment also led to increased T cell apop

4 DMF induced cell death in primary patient-derived CD4(+)

5 DMF is particularly well suited for analytical applicati

6 DMF protected WT and Nrf2(-/-) mice equally well from de

7 DMF treatment delayed the growth of CTCL tumors and prev

8 DMF treatment is of particular promise in CTCL because D

9 DMF treatment reduced neurological deficit, immune cell

10 DMF-induced cell death was linked specifically to NF-kap

11 DMF=N,N-dimethylformamide, Tf=trifluoromethanesulfonyl,

12 compounds (NBu(4))(2)[ReCl(4)(CN)(2)] (1), (DMF)(4)ZnReCl(4)(CN)(2) (2), and [(PY5Me(2))(2)Mn(2)ReCl

13 ll of 20 tripodal capping ligands (L) and 12 DMF ligands.

14 enzene-1,3,5-tricarboxylate), and [Ca3(btc)2(DMF)2(H2O)2].3H2O are proven on aqueous solutions of fiv

15 For [Ca3(BTC)2(DMF)2(H2O)2].3H2O, it is added as a third MOF component

16 te based ultramicroporous MOF, 1 [Ni-(4PyC)2.DMF], that has the lowest PE for postcombustion CO2 capt

17 ormation of Co-BTTri (Co3[(Co4Cl)3(BTTri)8]2.DMF), a sodalite-type metal-organic framework.

18 framework Co-BDTriP (Co3[(Co4Cl)3(BDTriP)8]2.DMF; H3BDTriP = 5,5'-(5-(1H-pyrazol-4-yl)-1,3-phenylene)

19 , [{(Zn(0.25))(8)(O)}Zn(6)(L)(12)(H(2)O)(29)(DMF)(69)(NO(3))(2)](n) (1) {H(2)L = 1,3-bis(4-carboxyphe

20 rganic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

21 rmal crystallisation of a new MOF [Yb2(BDC)3(DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dim

22 Under more enforcing conditions (AgNO(3), DMF, 100 degrees C, 18 h), the initially formed products

23 s under relatively mild conditions (AgNO(3), DMF, 60 degrees C, 1 h) to give 3-amino-2,3-dihydro-2-ar

24 ZIF-8-along with as-synthesized ZIF-4 (ZIF-4.DMF) and ball-milling amorphized ZIF-4 (a(m)ZIF-4) were

25 dimethylformamide (DMF) in the case of ZIF-4.DMF.

26 emiconductors, [Fe(tpma)(xbim)](X)(TCNQ)(1.5)DMF (X=ClO4(-) or BF4(-); tpma=tris(2-pyridylmethyl)amin

27 sentative examples, [CuCl(phen)(PCN)].DMF (5.DMF) and [CuBr(dpq)(PCN)].2DMF (10.2DMF).

28 3,6-DMF corresponds to direct bond formation between ortho p

29 omethane generates 3,6-dimethylfluorene (3,6-DMF) and 2,7-dimethylfluorene (2,7-DMF), which were iden

30 2,7-DMF corresponds to a carbene-carbene rearrangement, wher

31 rene (3,6-DMF) and 2,7-dimethylfluorene (2,7-DMF), which were identified by fluorescence measurements

32 Upon soaking in a DMF solution of Cp2Co, the compound undergoes a single-c

33 he optimum configuration is implemented on a DMF platform with an interdigitated capacitive biosensor

34 hyl acetate, acetone, alcohol, acetonitrile, DMF, and DMSO, identify complex solvent systems, as well

35 In addition, DMF abrogated TGFbeta/Akt1 mediated inhibitory phosphory

36 In addition, DMF induced increased cell death in primary CTCL tumors

37 In addition, DMF inhibits cell proliferation and significantly impair

38 ory Th2 subset (CCR3(+)) was increased after DMF treatment.

39 Although DMF did not eliminate the possibility of disease reactiv

40 DMF)2]H2O (BDC=benzene-1,4-dicarboxylate and DMF=N,N-dimethylformamide) under solvothermal conditions

41 examined and compared the effects of EP and DMF on MS-relevant activity/functions of T cells, macrop

42 ere also found for DMF, implying that EP and DMF share common targets and mechanisms of action.

43 loromethyl (1R,2S,5R)-(-)-menthyl ether, and DMF are used.

44 s a CuI catalyst, a AgF fluoride source, and DMF, pyridine, or DMPU solvent at moderately elevated te

45 ploying K2CO3 as a base in refluxing THF and DMF at 80 degrees C, respectively, delivers 2-aroylbenzo

46 PY to the chlorin moiety in both toluene and DMF and exhibits intense fluorescence of chlorin upon ex

47 BINAP in two different solvents, toluene and DMF.

48 Mixing of water and DMF is an exothermic process where the micelle formation

49 toward different proton (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or elec

50 1,3,5-(4-formylphenyl)-benzene in anhydrous DMF afforded porous BILP-15 (448 m(2) g(-1)) and BILP-16

51 and occurs at ambient temperature in aqueous DMF in an undivided cell open to air.

52 at support intermolecular H-bonding, such as DMF and DMSO, leading to efficient intramolecular photor

53 on experiments using polar solvents, such as DMF, no "mixed" products possessing structurally differe

54 ent is of particular promise in CTCL because DMF is already in successful clinical use in the treatme

55 number of relapses and MRI parameters before DMF treatment were good predictors of disease activity d

56 on between Li(+) and the oxygen atom of both DMF and DMA that increases the extent of positive charge

57 Buffered DMF:DMF(H)(+) mixtures afforded an increase in the catal

58 icrowave irradiation in a solution of t-BuOK/DMF-d7.

59 re greater than those easily accommodated by DMF devices and contain analytes of interest at low conc

60 mediating the protective effect afforded by DMF in EAE, a mouse model of MS.

61 The protection afforded by DMF is mediated in part through inhibiting oxidative str

62 ifying enzyme, was significantly enhanced by DMF administration in kidney.

63 itially coordinated to Yb(3+) is replaced by DMF as the reaction progresses.

64 n (4-nitrophenol and [DMF.H(+)](CF3SO3(-))) (DMF = dimethyl-formamide) or electron (decamethylferroce

65 e-shaped solvation intermediates (CH3NH3PbI3.DMF and CH3NH3PbI3.H2O) have been recognized as the main

66 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multiplexed methods tha

67 in the compound (K[222-crypt])4 [Sn14 Ni(CO)]DMF.

68 ced in solvent of high dielectric constants (DMF), most likely by photoinduced electron transfer.

69 20 mg/kg per day intraperitoneally) or CsA + DMF (n = 7, 50 mg/kg per day orally) for 28 days.

70 creatinine (CsA 0.79 +/- 0.02 mg/dL vs CsA + DMF 0.62 +/- 0.04 mg/dL, P = 0.001) and urea (CsA 66.9 +

71 1) and urea (CsA 66.9 +/- 0.4 mg/dL vs CsA + DMF 53.3 +/- 2.6 mg/dl, P < 0.0001) levels, as well as i

72 agent, N,N-dimethylformamide dimethylacetal (DMF-DMA) and tetramethylammonium hydroxide (TMAH) as met

73 ormamidine (DMPF) and 2,4-dimethylformamide (DMF) into 2,4-dimethylaniline (DMA), directly from QuECh

74 NTs were assembled from a dimethylformamide (DMF) suspension onto a carbon-fiber disk microelectrode

75 is basic solvents such as dimethylformamide (DMF) compared with those in chloroform or dichloromethan

76 as synthesized by heating dimethylformamide (DMF) solution of the known Ni-centered and Ni(CO)-capped

77 sonication of graphite in dimethylformamide (DMF) upon addition of ferrocene aldehyde (Fc-CHO).

78 odecyl maltoside (DDM) in dimethylformamide (DMF), micelle formation can be induced simply by adding

79 entially binds with NR in dimethylformamide (DMF)/water (1:1) solution over other cations such as Fe(

80 duction of formic acid in dimethylformamide (DMF)/water mixtures (Faradaic efficiency of 90 +/- 10%)

81 imidazole linker, and N,N dimethylformamide (DMF) in the case of ZIF-4.DMF.

82 )benzene (H3BTTri) in N,N-dimethylformamide (DMF) and methanol leads to the formation of Co-BTTri (Co

83 action reactions from N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) by the cumyloxyl (C

84 adical (CumO(*)) with N,N-dimethylformamide (DMF) and N,N-dimethylacetamide (DMA) was studied by lase

85 ulfurizer, Fe(II) and N,N-dimethylformamide (DMF) are introduced to Fe(III)-IL to construct a new non

86 ction is performed in N,N-dimethylformamide (DMF) in a continuous membrane reactor which retains the

87 in the gas phase, in N,N-dimethylformamide (DMF) solution, and in DMF solution in the presence of te

88 unknown breakdown of N,N-dimethylformamide (DMF) to formaldehyde at high temperature under mildly ac

89 hylacetamide (DMA) or N,N-dimethylformamide (DMF) was used to improve the separation selectivity.

90 ination of CO2(*-) in N,N-dimethylformamide (DMF) with the tip generation/substrate collection (TG/SC

91 ylacetamide (DMA) and N,N-dimethylformamide (DMF), as the background electrolyte (BGE) to improve the

92 from the C-H bonds of N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), N-formylpyrrolidine (

93 st molecules, such as N,N-dimethylformamide (DMF).

94 ation during ozonation of dimethylformamide (DMF), the other model precursor used in this study, occu

95 ts is possible using only dimethylformamide (DMF) and tetrabromomethane (CBr4) in the bromination of

96 ng a cooperative solvent, dimethylformamide (DMF), to synthesize core/shell architectured gold-phosph

97 solution casting of their dimethylformamide (DMF) solutions under ambient conditions.

98 illing the MOF pores with dimethylformamide (DMF) slows the structural fluctuations by reducing the a

99 When using dimethylformamidium, DMF(H)(+), the mechanism of H2 formation by 1 changes fr

100 DISCUSSION: DMF appeared generally safe and no carryover PML among i

101 lles upon dialysis of the polymers from DMSO/DMF to aqueous buffer.

102 e in preventing the collapse of pores during DMF evaporation.

103 s Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the effectiv

104 urements) between a negligible value for Dy2-DMF and 76 cm(-1) for Dy2-CH3CN.

105 supporting the notion that the electrophile, DMF, acts via covalent modification.

106 The method employs DMF-water as the solvent and copper(II) acetate as the c

107 These results establish DMF as an NFkappaB inhibitor with anti-tumor activity th

108 In the presence of excess DMF such intermediates thermally react with a variety of

109 posure was associated with 11% and 10% fewer DMF-Teeth in the pre-1960 (p < .0001) and 1960-1990 coho

110 of both off-line and in-line MS analysis for DMF sample processing.

111 ion represents an important step forward for DMF, further enhancing its utility for a wide range of a

112 Most of these effects were also found for DMF, implying that EP and DMF share common targets and m

113 se results reveal a new molecular target for DMF and show that a clinically approved drug inhibits M1

114 m to existing inline analysis techniques for DMF.

115 the block in K63 and/or M1 chain formation, DMF inhibits NFkappaB and ERK1/2 activation, resulting i

116 the in situ generation of dimethylamine from DMF followed by nucleophilic aromatic substitution of a

117 Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) th

118 We show here that dimethyl fumarate (DMF) dose-dependently induces mitochondrial biogenesis a

119 Taken orally, the drug dimethyl fumarate (DMF) has been shown to improve functional outcomes for p

120 o explore the efficacy of dimethyl fumarate (DMF) in preventing disease reactivation after NTZ discon

121 Dimethyl fumarate (DMF) is an effective novel treatment for multiple sclero

122 Dimethyl Fumarate (DMF) is an FDA approved anti-oxidative and anti-inflamma

123 Dimethyl fumarate (DMF) is indicated for the treatment of relapsing multipl

124 the protective effects of dimethyl fumarate (DMF) on CsA-induced nephrotoxicity by enhancing the anti

125 vestigated the effects of dimethyl fumarate (DMF) on CTCL cells in vitro and in vivo.

126 Dimethyl fumarate (DMF) possesses anti-inflammatory properties and is appro

127 Dimethyl fumarate (DMF), a new drug for multiple sclerosis (MS) treatment,

128 need, we examined whether dimethyl fumarate (DMF), an anti-inflammatory drug already in clinical use

129 ng sulforaphane (SFN) and dimethyl fumarate (DMF), are unable to induce a similar response.

130 the CNS-penetrating drug dimethyl fumarate (DMF), decreased supernatant glutamate and neurotoxicity.

131 ic acid esters, including dimethyl fumarate (DMF, Tecfidera; Biogen, Cambridge, MA), have shown thera

132 Dimethyl fumarate (DMF; trade name Tecfidera) is an oral formulation of the

133 As described herein, DMF-IP and P-CLIP-DMF-IP are rapid, automated, and multi

134 and contributes to our understanding of how DMF may act clinically to ameliorate pathological proces

135 patients with MS; however, it is unclear how DMF mediates a protective effect.

136 However, DMF treatment in randomized controlled MS trials was ass

137 (O2CPh)(NO)2](BF4)2 (1a) and [Fe2(N-Et-HPTB)(DMF)2(NO)(OH)](BF4)3 (2a), are characterized by FTIR and

138 Fe(III/II)-IL/DMF can remove hydrogen sulfide and can be regenerated t

139 queous desulfurization system (Fe(III/II)-IL/DMF).

140 Importantly, DMF prevented bleomycin-induced skin fibrosis in mice.

141 In DMF as the solvent, the reaction half-lives for the conv

142 In DMF the complex shows three well-behaved redox waves in

143 In DMF, discrete droplets can be made to merge, mix, split,

144 In DMF, O-alkylation is faster than retroaldol-aldol rearra

145 In DMF/water (1:1, v/v), the receptor 1 showed a selectivit

146 e of 0.155-0.23 in toluene and 0.12-0.185 in DMF.

147 H2O (1) reacts with CF3SiMe3 and PhB(OH)2 in DMF at rt to give PhCF3 in >95% yield within 15 min.

148 so be effected by treating 5 with AgNO(3) in DMF at 100 degrees C for 18 h or BF(3).Et(2)O at rt.

149 bonate, and mesitylenic acid as additives in DMF solvent.

150 N,N-dimethylformamide (DMF) solution, and in DMF solution in the presence of tetramethylammonium ions

151 rylmethyl bromides using t-BuOK as a base in DMF, followed by Pd(0)-mediated intramolecular Heck coup

152 r solvothermal treatment at 200 degrees C in DMF.

153 nd 5-acetoxymethylpyrrole-2-carbaldehydes in DMF to give the crucial neo-confused dipyrrolic dialdehy

154 ence of Pd(OAc)2/Cs2CO3/PivOH combination in DMF (100 degrees C, 2 h) to yield 5-arylated uracils.

155 using Selectfluor in the presence of CsF in DMF at room temperature for 15-60 min provided beta-keto

156 n depending on the solvent applied (e.g., in DMF ranging from 0.25 to 0.53).

157 ions are observed under microwave heating in DMF.

158 tion of benzyl bromide and sodium hydride in DMF can lead to the formation of an amine side product,

159 ar Heck coupling in the presence of K2CO3 in DMF at 80-140 degrees C.

160 ce were similar for patients with lesions in DMF or mOFC/vmPFC, compared with Controls.

161 rs to decomplexation, which were measured in DMF-d7 for phenanthrene, pyrene, triphenylene, and coron

162 %) at moderate overpotentials (500-700 mV in DMF measured at the middle of the catalytic wave).

163 -3-yl)but-2-en-1-one (R = CH3) with R'NH2 in DMF at 50 degrees C for 24 h provides 2,3-dihydro-1,8-na

164 quinolizinium) in CH3CN to 507 and 553 nm in DMF, respectively.

165 the antiinflammatory contribution of Nrf2 in DMF treatment of the MS model, experimental autoimmune e

166 m salt of the peptide with FeSO(4).7H(2)O in DMF afforded the desired products in high purities (73-9

167 7-expressing CD4(+) T cells were observed in DMF-treated patients.

168 Cuprous oxide in DMF was found to be the optimal catalyst for the reactio

169 of dioxygen catalyzed by iron porphyrins in DMF as an example, decreasing [HA] 10-fold lowers etaeff

170 step single-pot synthesis occurs smoothly in DMF at rt.

171 ing rapid injection (1)H NMR spectroscopy in DMF-d7 at -55 degrees C revealed the barriers to complex

172 her simple arenes in the presence of TBAF in DMF without the necessity of adding any ligands or addit

173 ) are much larger in apolar solvents than in DMF.

174 air-stable Ni(II) precatalysts were used in DMF under CF lamp irradiation; however, O2 was not requi

175 isomer was formed regioselectively, while in DMF under similar reaction conditions the 2,3-diamino-6,

176 ated with the integration of biosensors into DMF: (1) complete removal of the droplet containing the

177 ted with preisolated or in situ-generated [K(DMF)][(t-BuO)2Cu] to give [K(DMF)2][(t-BuO)Cu(C2F5)] (1)

178 tu-generated [K(DMF)][(t-BuO)2Cu] to give [K(DMF)2][(t-BuO)Cu(C2F5)] (1) in nearly quantitative yield

179 ngth was modulated from weak to strong (L' = DMF, MeCN, CN).

180 2 (L3)(H2 O)2 ]n (NJU-Bai 42), and [Cu2 (L4)(DMF)2 ]n (NJU-Bai 43) were prepared and we observed that

181 Mean DMF-T was significantly higher in patients with RA (19.3

182 Mechanistically, DMF prevents p65 nuclear translocation and attenuates it

183 h different polarities (i.e., toluene, MeOH, DMF, and DMSO).

184 esidues of amitraz or its other metabolites, DMF and DMA, were extracted using the QuEChERS method.

185 high-throughput screening (HTS) methodology, DMF and NaHCO3 were rapidly identified as the most effec

186 hemical cell integrated in a microfabricated DMF device, removing the need for external electrodes an

187 detection coupled with digital microfluidic (DMF) devices has most commonly been demonstrated in an o

188 introduce an automated digital microfluidic (DMF) platform capable of performing immunoassays from sa

189 combines droplet-based digital microfluidic (DMF) sample handling with peripheral modules to create a

190 We report the first digital microfluidic (DMF) system capable of impedance sensing of mammalian ce

191 be positioned between digital microfluidics (DMF) addressing each droplet individually using 2D array

192 Digital microfluidics (DMF) is a powerful technique for simple and precise mani

193 Digital microfluidics (DMF) is an emerging technique for manipulating small vol

194 e in-line coupling of digital microfluidics (DMF) with HPLC-MS, using a custom, 3D-printed manifold a

195 Digital microfluidics (DMF), a microscale liquid handling technique characteriz

196 pulation mechanism in digital microfluidics (DMF), where droplets can be actuated over a (super)hydro

197 on of biosensors into digital microfluidics (DMF).

198 tegration of ECL with digital microfluidics (DMF).

199 ein G, manipulated by digital microfluidics (DMF).

200 agnetic particles and digital microfluidics (DMF-IP).

201 ividually and act as discrete microreactors, DMF is well suited for microscale sample processing.

202 solid-organic sodium ion electrolyte NaClO4 (DMF)3 (DMF=dimethylformamide) is described.

203 Pressed pellets of microcrystalline NaClO4 (DMF)3 exhibit a conductivity of 3x10(-4) S cm(-1) at roo

204 The crystal structure of NaClO4 (DMF)3 reveals parallel channels of Na(+) and ClO4(-) ion

205 on cooling, it resolidifies as solid NaClO4 (DMF)3 , permitting melt casting of the electrolyte into

206 t, compared to conventional methods, the new DMF approach reported here reduced reagent volumes and a

207 osyl diiron(II) complex, [Fe2(N-Et-HPTB)(NO)(DMF)3](BF4)3 (2).

208 uggest that the antiinflammatory activity of DMF in treatment of MS patients may occur through altern

209 teine 38 being essential for the activity of DMF.

210 The addition of DMF in Fe(III/II)-IL does not change the structure of Fe

211 Administration of DMF has a protective potential against CsA nephrotoxicit

212 Dimethyl succinate, the inactive analog of DMF that lacks the electrophilic double bond of fumarate

213 shelf agent, appears to be a redox analog of DMF, but its immunomodulatory properties have not been p

214 To combine the full capabilities of DMF with voltammetry, we designed a platform featuring a

215 Coordination of DMF to the [((H)L)2Fe6] core leads to weaker Fe-Fe inter

216 The beneficial effect of DMF treatment in Nrf2(-/-) and WT mice was accompanied b

217 es a mechanism of the antifibrotic effect of DMF via inhibition of Akt1/GSK3beta/TAZ/YAP signaling an

218 2) is required for the therapeutic effect of DMF.

219 his study was to assess the effectiveness of DMF as a therapy for PAH using patient-derived cells and

220 Our findings indicate that effects of DMF are facilitated by inhibiting pro-inflammatory NFkap

221 t HCA(2) mediates the therapeutic effects of DMF in EAE.

222 al results demonstrate beneficial effects of DMF on key molecular pathways contributing to PAH, and s

223 ibitor H89 partially mimicked the effects of DMF on the DC signaling pathway and impaired DC maturati

224 AP recapitulated the antifibrotic effects of DMF.

225 o evidence of disease activity at the end of DMF treatment.

226 To study the impact of DMF in vivo, we developed 2 CTCL xenograft mouse models

227 However, examples of the integration of DMF with electroanalytical methods are notably scarce, a

228 fumarate (MMF), the bioactive metabolite of DMF, which can stabilize NRF2 and induce antioxidant gen

229 handling has been beneficial for a number of DMF-based applications, including proteomics, chemical s

230 and it was attributable to the oxidation of DMF by hydroxyl radicals.

231 fabricated into the ITO-coated top plates of DMF devices, allowing for the generation of light from e

232 ing the automated sample processing power of DMF with the resolving and analytical capacity of HPLC-M

233 nthesized and used a novel chemical probe of DMF by incorporating an alkyne functionality and found t

234 Upon removal of DMF and H2O solvent molecules, the compound undergoes a

235 help to evaluate the efficacy and safety of DMF treatment.

236 This study supports the use of DMF as a treatment for SSc dermal fibrosis.

237 were exclusively obtained, while the use of DMF at 60 degrees C gave selectively 12H-benzoannulen[b]

238 2 years of NTZ treatment and the 2 years of DMF were collected.

239 ondrial gene expression is more dependent on DMF's target Nrf2 than hydroxycarboxylic acid receptor 2

240 Addition of DMA or DMF to the BGE impacts separation selectivity through di

241 olvent such as methanol, aqueous ethanol, or DMF or in biphasic mixtures that use acetonitrile.

242 changes in bulk solvent (water, methanol, or DMF) or applied pressure (up to 150 MPa) affect the rota

243 Following oral DMF administration, central nervous system (CNS) tissue

244 Our observations that oral DMF treatment promoted immune modulation and provided eq

245 -55) for EAE induction and treated with oral DMF or vehicle daily.

246 In particular, DMF decreased the number of infiltrating neutrophils in

247 o representative examples, [CuCl(phen)(PCN)].DMF (5.DMF) and [CuBr(dpq)(PCN)].2DMF (10.2DMF).

248 ere), mOFC/vmPFC, or dorsomedial prefrontal (DMF), and a comparison group of healthy age- and educati

249 vinylidene fluoride)/dimethylformamide (PVDF/DMF) was used to coat the tip of each fiber to increase

250 Bu(3)SnH reduces DMF, but along with the low yields of Bu(3)SnOSnBu(3) (b

251 ermeable thiol N-acetyl l-cysteine, reverses DMF inhibition of the NFkappaB pathway, supporting the n

252 sulfate complex which encapsulates a single DMF in the tripodal cavity of the receptor.

253 r in the one-dimensional coordination solid (DMF)(4)MnReCl(4)(CN)(2) (4).

254 ed free energy of 5.9 kcal/mol, in solution (DMF via C-PCM approach).

255 the phases Dy2(INO)4(NO3)22 solvent (solvent=DMF (Dy2-DMF), CH3CN (Dy2-CH3CN)), thereby switching the

256 In summary, DMF treatment represents a remarkable therapeutic option

257 recorded decayed, missing, and filled teeth (DMF-Teeth) and decayed and filled tooth surfaces (DF-Sur

258 decayed, missing, and/or filled adult teeth [DMF-T] index); 2) gingival inflammation (papillary bleed

259 We find that DMF inhibits pro-inflammatory cytokine production in res

260 We found that DMF blocks the profibrotic effects of transforming growt

261 ating an alkyne functionality and found that DMF covalently modifies p65, with cysteine 38 being esse

262 We found that DMF effectively blocks NFkappaB activity in multiple bre

263 Mechanistically, we found that DMF treatment reduced nuclear localization of transcript

264 ndent mammosphere formation, indicating that DMF has anti-cancer stem cell properties.

265 The observation that DMF stimulates mitochondrial biogenesis, gene expression

266 We propose that DMF-ECL represents a valuable new tool in the microfluid

267 Instead we show that DMF can inhibit the E2 conjugating enzymes involved in K

268 We show that DMF treatment is effective in reversing hemodynamic chan

269 We further showed that DMF significantly diminished nuclear TAZ/YAP localizatio

270 Our results suggest that DMF acts on specific memory and effector T cell subsets

271 The DMF cotreatment ameliorated CsA-induced renal dysfunctio

272 The DMF impedance system is label-free, does not require ima

273 imal geometry of the sensing surface and the DMF platform providing successful removal of the target

274 During the DMF phase, among the 39 patients, one or more relapses o

275 s into a narrow region on the surface of the DMF device, facilitating up to eight simultaneous digita

276 ndergo deformations, and the dynamics of the DMF molecules are also greatly restricted.

277 nto account the overall configuration of the DMF platform.

278 The performance of the DMF/voltammetry system is comparable to that of a commer

279 tion in microscale volumes (5-15 muL) on the DMF device itself.

280 ample through a 10 muL droplet region on the DMF device, enabling magnet-mediated recovery of bead-bo

281 ical and radiological activity preceding the DMF treatment might be used as a prognostic marker of th

282 NO)](-) (3) and [Fe(III)(SH)4](-) (5) in THF/DMF spontaneously dimerized into the first structurally

283 containing Polywax with toluene, THF, or THF/DMF at ca. 80 degrees C.

284 Thus, DMF induces mitochondrial biogenesis primarily through i

285 s applicable to all biosensors integrated to DMF.

286 high risk of PML, were switched from NTZ to DMF and underwent neurological and 3T MRI monitoring for

287 The world-to-DMF system is designed for flexibility in accommodating

288 allenge, we have developed a novel "world-to-DMF" interface in which an integrated companion module d

289 -methylation of ketones via enaminones using DMF dimethyl acetal as carbon source.

290 er solvothermal conditions, from mixed water/DMF solvent.

291 e in a counter-current membrane system where DMF is continuously replaced by ethanol.

292 To determine whether DMF interacts directly with p65, we synthesized and used

293 se models, prompting us to determine whether DMF is effective as a treatment for SSc dermal fibrosis.

294 With DMF, a solvent-induced change in HAT selectivity was obs

295 With DMF, abstraction occurs from the formyl and N-methyl C-H

296 Coupling the versatility of MS analysis with DMF sample handling has been beneficial for a number of

297 sed and the CD4/CD8 ratio was increased with DMF treatment.

298 T cell activation was reduced with DMF treatment, especially among effector memory T cells

299 rs of disease activity during treatment with DMF.

300 ies ranging from 2400 to 27,000 s(-1) with [(DMF)H](+) in acetonitrile.